Unable to load price data. Sorry.

¯\_(ツ)_/¯

Brickell Biotech, Inc. (NASDAQ:BBI)

CAPS Rating: 1 out of 5

The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

Unable to load market data for this Ticker. Sorry.

¯\_(ツ)_/¯

Caps

How do you think NASDAQ:BBI will perform against the market?

Add Stock to CAPS Watchlist

All Players

164 Outperform
16 Underperform
 

All-Star Players

25 Outperform
8 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top NASDAQ:BBI Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

SqwiiTrader (< 20)
Submitted March 18, 2014

prediction TOS

zzlangerhans (99.73)
Submitted December 17, 2012

Vical has concluded yet again that patients in the phase III trial of Allovectin-7 are living longer than expected, resulting in another lengthy delay before topline data will be released. Naturally, Vical bulls see this as a positive, concluding… More

Recent Community Commentary

Read the most recent pitches from players about BBI.

Recs

1
Member Avatar SqwiiTrader (< 20) Submitted: 3/18/2014 7:03:47 PM : Outperform Start Price: $9.24 NASDAQ:BBI Score: -149.32

prediction TOS

Recs

0
Member Avatar 10qdetective (< 20) Submitted: 3/4/2014 1:45:46 AM : Outperform Start Price: $10.57 NASDAQ:BBI Score: -159.62

Potential buyer in Merck?

Vical (VICL) is developing Allovectin, a first-in-class investigational DNA-based immunotherapeutic designed to stimulate both innate and adaptive immune responses in local tumors and distal metastases.

Of unique interest to Merck is that this immunotherapy is currently being evaluated in late-stage clinical trials as first-line treatment for Stage III and IV melanoma. Merck watchers might want to know, too, that Vical’s current CEO, Vijay Samant, previously spent 20 years with Merck in international sales and marketing.

Recs

0
Member Avatar rknapton (80.48) Submitted: 8/22/2013 5:22:16 PM : Underperform Start Price: $9.45 NASDAQ:BBI Score: +182.33

Short. Revenues declining. POS biotech.

Leaderboard

Find the members with the highest scoring picks in BBI.

Score Leader

mjonesy1985

mjonesy1985 (97.85) Score: +551.87

The Score Leader is the player with the highest score across all their picks in BBI.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
rhinomaj 92.92 8/4/2009 Underperform 3M $26.46 -97.45% +211.77% +309.21 0 Comment
etaster 44.38 12/3/2009 Underperform 1Y $20.44 -96.69% +179.77% +276.46 0 Comment
PIGMA 26.25 6/2/2011 Underperform 5Y $25.97 -97.40% +136.00% +233.40 0 Comment
elayton < 20 4/24/2008 Underperform 3W $25.41 -97.34% +135.65% +232.99 0 Comment
FUZZYMINKINS < 20 7/11/2011 Underperform 5Y $30.03 -97.75% +134.60% +232.35 0 Comment
cIRCitmage < 20 2/8/2011 Underperform NS $14.21 -95.24% +135.77% +231.01 0 Comment
gogogoo 73.02 1/30/2007 Underperform 3Y $44.31 -98.47% +131.58% +230.05 0 Comment
dwn88ir 61.53 4/23/2012 Underperform 5Y $19.81 -96.59% +128.09% +224.68 0 Comment
petricko 93.19 7/17/2007 Underperform 3W $36.05 -98.12% +111.35% +209.48 0 Comment
rknapton 80.48 8/27/2013 Underperform 5Y $9.45 -92.85% +89.48% +182.33 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BBI.